CSPC PHARMACEUT.GR. ADR4 (CVGU) - Total Assets
Based on the latest financial reports, CSPC PHARMACEUT.GR. ADR4 (CVGU) holds total assets worth €46.70 Billion EUR (≈ $54.59 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can CSPC PHARMACEUT.GR. ADR4 service its debt to assess how comfortably operating cash covers total debt obligations.
CSPC PHARMACEUT.GR. ADR4 - Total Assets Trend (2021–2025)
This chart illustrates how CSPC PHARMACEUT.GR. ADR4's total assets have evolved over time, based on quarterly financial data. See CVGU total equity for net asset value and shareholders' equity analysis.
CSPC PHARMACEUT.GR. ADR4 - Asset Composition Analysis
Current Asset Composition (December 2025)
CSPC PHARMACEUT.GR. ADR4's total assets of €46.70 Billion consist of 47.7% current assets and 52.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 13.0% |
| Accounts Receivable | €4.78 Billion | 10.2% |
| Inventory | €3.09 Billion | 6.6% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €2.77 Billion | 5.9% |
| Goodwill | €234.90 Million | 0.5% |
Asset Composition Trend (2021–2025)
This chart illustrates how CSPC PHARMACEUT.GR. ADR4's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is CSPC PHARMACEUT.GR. ADR4 worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CSPC PHARMACEUT.GR. ADR4's current assets represent 47.7% of total assets in 2025, a decrease from 58.5% in 2021.
- Cash Position: Cash and equivalents constituted 13.0% of total assets in 2025, down from 26.7% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 1.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 10.2% of total assets.
CSPC PHARMACEUT.GR. ADR4 Competitors by Total Assets
Key competitors of CSPC PHARMACEUT.GR. ADR4 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$207.62 Billion |
|
AstraZeneca PLC
NYSE:AZN
|
USA | $114.02 Billion |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436
|
China | CN¥18.38 Billion |
|
Aurora Optoelectronics Co Ltd
SHG:600666
|
China | CN¥2.22 Billion |
|
NanJing Pharmaceutical Co Ltd
SHG:600713
|
China | CN¥34.05 Billion |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$3.66 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
CSPC PHARMACEUT.GR. ADR4 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.19 | 2.27 | 2.54 |
| Quick Ratio | 1.88 | 1.95 | 2.22 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €12.07 Billion | €12.25 Billion | €16.03 Billion |
CSPC PHARMACEUT.GR. ADR4 - Advanced Valuation Insights
This section examines the relationship between CSPC PHARMACEUT.GR. ADR4's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.21 |
| Latest Market Cap to Assets Ratio | 0.24 |
| Asset Growth Rate (YoY) | 5.2% |
| Total Assets | €46.70 Billion |
| Market Capitalization | $11.04 Billion USD |
Valuation Analysis
Below Book Valuation: The market values CSPC PHARMACEUT.GR. ADR4's assets below their book value (0.24x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: CSPC PHARMACEUT.GR. ADR4's assets grew by 5.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for CSPC PHARMACEUT.GR. ADR4 (2021–2025)
The table below shows the annual total assets of CSPC PHARMACEUT.GR. ADR4 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €46.70 Billion ≈ $54.59 Billion |
+5.20% |
| 2024-12-31 | €44.39 Billion ≈ $51.90 Billion |
-4.09% |
| 2023-12-31 | €46.28 Billion ≈ $54.11 Billion |
+10.80% |
| 2022-12-31 | €41.77 Billion ≈ $48.83 Billion |
+20.23% |
| 2021-12-31 | €34.74 Billion ≈ $40.62 Billion |
-- |
About CSPC PHARMACEUT.GR. ADR4
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining cap… Read more